Spago Nanomedical AB (publ) (SPAGO.ST)
SEK 0.19
(7.39%)
SEK 0.19
(7.39%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -23.28 Million SEK | -45.78% |
| 2022 | -15.6 Million SEK | 6.99% |
| 2021 | -16.77 Million SEK | -3932.69% |
| 2020 | -416 Thousand SEK | -115.68% |
| 2019 | 2.65 Million SEK | -93.07% |
| 2018 | 38.28 Million SEK | 354.78% |
| 2017 | 8.41 Million SEK | 18.76% |
| 2016 | 7.08 Million SEK | -44.35% |
| 2015 | 12.73 Million SEK | 156.89% |
| 2014 | 4.95 Million SEK | 31.89% |
| 2013 | 3.76 Million SEK | -20.17% |
| 2012 | 4.71 Million SEK | 1.36% |
| 2011 | 4.64 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -5.91 Million SEK | -18.09% |
| 2024 Q2 | -6.14 Million SEK | 47.81% |
| 2023 Q2 | -2.68 Million SEK | 71.69% |
| 2023 Q3 | -2.22 Million SEK | 17.05% |
| 2023 FY | -22.74 Million SEK | -45.78% |
| 2023 Q4 | -5 Million SEK | -125.24% |
| 2023 Q1 | -9.46 Million SEK | -74.62% |
| 2022 FY | -15.6 Million SEK | 6.99% |
| 2022 Q1 | -3.82 Million SEK | 33.25% |
| 2022 Q4 | -5.42 Million SEK | -72.62% |
| 2022 Q3 | -3.14 Million SEK | 2.42% |
| 2022 Q2 | -3.21 Million SEK | 15.78% |
| 2021 Q3 | -5.38 Million SEK | -2.03% |
| 2021 Q1 | -396 Thousand SEK | -210.0% |
| 2021 Q4 | -5.72 Million SEK | -6.43% |
| 2021 Q2 | -5.27 Million SEK | -1231.57% |
| 2021 FY | -16.77 Million SEK | -3932.69% |
| 2020 FY | -416 Thousand SEK | -115.68% |
| 2020 Q1 | -62 Thousand SEK | -101.89% |
| 2020 Q2 | 1.07 Million SEK | 1827.42% |
| 2020 Q3 | -283 Thousand SEK | -126.42% |
| 2020 Q4 | 360 Thousand SEK | 227.21% |
| 2019 Q2 | 831 Thousand SEK | -86.35% |
| 2019 Q4 | 3.28 Million SEK | -52.3% |
| 2019 Q3 | 6.89 Million SEK | 729.24% |
| 2019 FY | 2.65 Million SEK | -93.07% |
| 2019 Q1 | 6.08 Million SEK | -44.01% |
| 2018 Q1 | 10.06 Million SEK | 329.07% |
| 2018 Q3 | 9.04 Million SEK | 8.95% |
| 2018 Q4 | 10.87 Million SEK | 20.26% |
| 2018 FY | 38.28 Million SEK | 354.78% |
| 2018 Q2 | 8.3 Million SEK | -17.53% |
| 2017 Q3 | 5.46 Million SEK | 5.44% |
| 2017 Q4 | 2.34 Million SEK | -57.06% |
| 2017 FY | 8.41 Million SEK | 18.76% |
| 2017 Q1 | 1.77 Million SEK | -67.83% |
| 2017 Q2 | 5.18 Million SEK | 191.56% |
| 2016 Q1 | 1.54 Million SEK | -45.75% |
| 2016 FY | 7.08 Million SEK | -44.35% |
| 2016 Q4 | 5.52 Million SEK | 192.58% |
| 2016 Q3 | 1.88 Million SEK | -53.96% |
| 2016 Q2 | 4.1 Million SEK | 165.78% |
| 2015 Q3 | 3.29 Million SEK | -8.34% |
| 2015 Q2 | 3.59 Million SEK | 19.63% |
| 2015 Q1 | 3 Million SEK | 28.2% |
| 2015 Q4 | 2.84 Million SEK | -13.69% |
| 2015 FY | 12.73 Million SEK | 156.89% |
| 2014 FY | 4.95 Million SEK | 31.89% |
| 2014 Q4 | 2.34 Million SEK | 85.74% |
| 2014 Q3 | 1.26 Million SEK | -14.9% |
| 2014 Q2 | 1.48 Million SEK | -62.19% |
| 2014 Q1 | 3.92 Million SEK | 1924.19% |
| 2013 Q1 | 1.27 Million SEK | -2.16% |
| 2013 Q3 | 1.4 Million SEK | 8.64% |
| 2013 Q4 | -215 Thousand SEK | -115.27% |
| 2013 FY | 3.76 Million SEK | -20.17% |
| 2013 Q2 | 1.29 Million SEK | 1.97% |
| 2012 FY | 4.71 Million SEK | 1.36% |
| 2012 Q4 | 1.29 Million SEK | 4.67% |
| 2012 Q2 | 1.12 Million SEK | 7.26% |
| 2012 Q3 | 1.24 Million SEK | 10.51% |
| 2012 Q1 | 1.04 Million SEK | 0.0% |
| 2011 FY | 4.64 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 85.51% |
| Ziccum AB (publ) | -23.28 Million SEK | 0.013% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 106.723% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 155.718% |
| Mendus AB (publ) | 28.48 Million SEK | 181.732% |
| Genovis AB (publ.) | 54 Million SEK | 143.116% |
| Intervacc AB (publ) | -13.79 Million SEK | -68.791% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 1172.455% |
| Active Biotech AB (publ) | -1.67 Million SEK | -1290.03% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 333.695% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 186.809% |
| Aptahem AB (publ) | 2.63 Million SEK | 985.067% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -580.59% |
| Kancera AB (publ) | -1.96 Million SEK | -1084.885% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 30337.662% |
| Fluicell AB (publ) | 1.73 Million SEK | 1439.643% |
| Saniona AB (publ) | 11.78 Million SEK | 297.632% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -355.013% |
| Biovica International AB (publ) | 6.87 Million SEK | 438.563% |
| AcouSort AB (publ) | 8.38 Million SEK | 377.542% |
| Xintela AB (publ) | 78 Thousand SEK | 29950.0% |
| Abliva AB (publ) | -35.66 Million SEK | 34.714% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 84.15% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 929.462% |
| OncoZenge AB (publ) | 3000.00 SEK | 776200.0% |
| Amniotics AB (publ) | -1.93 Million SEK | -1106.373% |
| 2cureX AB (publ) | -37.48 Million SEK | 37.89% |
| CombiGene AB (publ) | -21.29 Million SEK | -9.358% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -5404.255% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 102.061% |
| Camurus AB (publ) | 1.58 Billion SEK | 101.473% |
| Corline Biomedical AB | 28.38 Million SEK | 182.04% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 81.03% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 32.346% |
| I-Tech AB | 27.56 Million SEK | 184.463% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 132.816% |
| Cyxone AB (publ) | 2.61 Million SEK | 991.727% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 784.19% |
| Biosergen AB | -456 Thousand SEK | -5005.921% |
| Cantargia AB (publ) | -3.45 Million SEK | -574.674% |
| NextCell Pharma AB | -43.74 Million SEK | 46.779% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | -153.241% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 307.545% |
| Nanologica AB (publ) | -76 Thousand SEK | -30535.526% |
| SynAct Pharma AB | -778 Thousand SEK | -2892.674% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -11963.731% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | -80.181% |
| Lipum AB (publ) | 53 Thousand SEK | 44030.189% |
| BioInvent International AB (publ) | 71.46 Million SEK | 132.581% |
| Alzinova AB (publ) | 19.87 Million SEK | 217.153% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 164.142% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 1691.434% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -155120.0% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 1504.282% |
| Simris Alg AB (publ) | 2 Million SEK | 1260.09% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -550.363% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 165.793% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -2119.542% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 843.154% |